The FDA has granted approval for Daiichi Sankyo's Dato-DXd for breast cancer treatment, marking the drug's first US approval and second global authorization. This unexpected early approval strengthens the company's market position, with additional potential in non-small-cell lung cancer (NSCLC) treatment on the horizon.